Active, not recruitingPhase 2NCT05296512
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
Studying Clear cell adenocarcinoma of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Elizabeth K. Lee MD
- Principal Investigator
- Elizabeth K Lee, MDDana-Farber Cancer Institute
- Intervention
- Lenvatinib(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2022 – 2028
Study locations (3)
- University of Chicago Medicine, Chicago, Illinois, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05296512 on ClinicalTrials.govOther trials for Clear cell adenocarcinoma of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06677190Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginDana-Farber Cancer Institute
- RECRUITINGPHASE1, PHASE2NCT06065462Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100M.D. Anderson Cancer Center
- RECRUITINGNCT06279104A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the OvaryTongji Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05032040A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05226507A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNuvectis Pharma, Inc.
- RECRUITINGPHASE1, PHASE2NCT04104776A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT03348631Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerNational Cancer Institute (NCI)